Innovation in the Lyme Disease Diagnostic Market is currently focused on T-cell response assays, such as Interferon Gamma Release Assays (IGRA). Unlike antibody tests that look for the body's reaction to the bacteria, IGRAs measure the activation of T-cells, which can be detected much earlier in the infection cycle. To stay updated on these future technologies, refer to the Lyme Disease Diagnostic Market forecast.

People also ask: What is the T-Detect Lyme test? How is T-cell testing different from antibody testing? These tests are gaining traction because they can potentially distinguish between an active infection and a past exposure, a long-standing challenge for traditional serology.

The T-cell segment is expected to capture a significant portion of the "early detection" market over the next decade. As these assays receive further clinical validation and regulatory approval, they may eventually complement or even replace the standard two-tier testing protocol for acute Lyme disease.